Immobilized human TNF-α at 0.5 μg/ml (50μL/well) can bind to Adalimumab with a linear range of 0.305 ng/ml to 5 μg/ml.
Product Details
Product Details
Product Specification
Host | Human |
Synonyms | Tumor necrosis factor, Cachectin, Tumor necrosis factor ligand superfamily member 2 (TNF-a), TNF, TNFA, TNFSF2 |
Accession | P01375 |
Clone Number | S-SC021 |
Antibody Type | Recombinant mAb |
Isotype | IgG1,k |
Application | Blocking of TNF alpha signaling Functional assays |
Purification | Protein A |
Concentration | 2 mg/ml |
Endotoxin | <1EU/mg |
Conjugation | Unconjugated |
Physical Appearance | Liquid |
Storage Buffer | PBS pH7.4, containing no preservative |
Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
application | dilution | species |
ELISA | 0.305-5000 ng/ml |
Background
Adalimumab is a fully human anti–tumor necrosis factor α (anti-TNFα) monoclonal antibody that specifically blocks the interaction of TNFα with its receptors. It binds both soluble and transmembrane TNFα. It is used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis.
Picture
Picture
ELISA
